Guy named Michael Shulman, analyst with some firm which I did not catch, named DNDN as one of his biotech picks due for a 'breakout' (his words) in 2006.
Also said it is currently out of favor, but the fda seems to support them.
Also said the results of their trials were very positive (can't remember the precise words he used).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.